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Background: Pancreatic enzyme replacement therapy is critical for adequate nutrition in cystic fibrosis (CF) patients with exocrine pancreatic
insufficiency (EPI).
Methods: This was a double-blind, randomised, placebo-controlled, two-period crossover study assessing efficacy and safety of Creon 24,000-unit
capsules in CF subjects ≥12 years with EPI. Patients were randomised to one of two 5-day sequences, Creon/placebo or placebo/Creon (target
dose, 4000 lipase units/g fat). Primary outcome was the coefficient of fat absorption (CFA); secondary outcomes were coefficient of nitrogen
absorption (CNA), symptoms, and safety.
Results: Thirty-two subjects were randomised. Mean CFA and CNA were significantly greater with Creon than placebo (CFA, 88.6% vs. 49.6%;
CNA, 85.1% vs. 49.9%; pb0.001 for both). Symptoms were improved and fewer treatment-emergent adverse events were reported with Creon
than placebo. One patient discontinued for weight loss unrelated to study drug.
Conclusions: This study demonstrated Creon was effective in treating EPI due to CF and was safe and well tolerated.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Coefficient of fat absorption; Coefficient of nitrogen absorption; Pancreatic enzyme replacement therapy; Pancrelipase; Pancreatin; Randomised,
controlled trial1. Introduction
Exocrine pancreatic insufficiency (EPI) occurs in as many as
85% to 90% of individuals with cystic fibrosis (CF) [1]. The
resulting lack of digestive enzymes leads to intestinal maldigestion☆ Previously presented at Digestive Disease Week, May 30–Jun 04, 2009,
Chicago, IL, USA, and the 32nd European Cystic Fibrosis Society Conference,
June 10–13, 2009, Brest, France.
⁎ Corresponding author. University of Cincinnati, Cincinnati Children's
Hospital Medical Center, Divisions of Pulmonary Biology and Pulmonary
Medicine, and Division of Pulmonary, Sleep, and Critical Care Medicine, 3333
Burnet Avenue, Cincinnati, OH45229. Tel.: (513) 636 6361; fax: (513) 636 3723.
E-mail address: bruce.trapnell@cchmc.org (B.C. Trapnell).
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doi:10.1016/j.jcf.2009.08.008with resultant malabsorption [2]. If left untreated, EPI can cause
steatorrhoea, abdominal cramping, severe discomfort, frequent
stools, and other adverse gastrointestinal symptoms and leads to
failure to thrive in infants, poor growth in children, and weight loss
in adults [3,4].
Typically, EPI is treated with pancreatic enzyme replacement
therapy, with the goal of restoring normal digestion and achieving
and maintaining adequate nutritional status [2]. Enzyme replace-
ment therapy is generally considered safe, effective, and well
tolerated based on a limited number of clinical trials and extensive
clinical experience. For example, pancrelipase (pancreatin)
delayed-release capsules, USP (Creon®, Solvay Pharmaceuticals,
Inc., Marietta, GA, USA) have been available in the United Statesd by Elsevier B.V. All rights reserved.
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effective in randomised clinical trials [5–7]. Pancreatic enzyme
supplementswere developed prior to enactment of theUSFood and
DrugAdministration (FDA)drug approval requirements.However,
in response to reports of adverse events (AEs) associated with high
doses of some enzyme supplements [8] and a lack of therapeutic
effect of some preparations [9], the FDA ruled in 2004 that
manufacturers of pancreatic enzyme supplements must file new
drug applications to ensure consistent efficacy, safety, and quality
of these agents [10].
A new formulation of Creon capsules has been developed to
comply with the new 2004 FDA mandate. Part of this mandate
requires manufacturers to target actual lipase activity at 100% of
the label claim [11]. Historically, these products have been
manufactured to meet USP standards of 90% to 165% lipase
activity of label claims. This reformulation containing 6000,
12,000, or 24,000units of lipase is comparable in terms of lipase
activity to currently marketed Creon capsules labelled as 5000,
10,000, and 20,000 lipase units. In addition, light mineral oil has
been removed from the pellets and dibutyl phthalate has been
removed from the enteric coating in response to general FDA and
EU directives, respectively.
The current study was designed to assess the efficacy of the
reformulated Creon 24,000-unit capsule (at a target dose of
4000 lipase units/g fat) in improving fat absorption, protein
absorption, and the effects on clinical symptoms of malabsorp-
tion in individuals with CF. Safety and tolerability also were
evaluated. A preliminary account of this study has been
presented in abstract form [12].
2. Methods
This study used a double-blind, randomised, placebo-controlled
two-arm, crossover design and was conducted at 10 centres in the
United States between November 15, 2007 and March 6, 2008
(NCT00510484). The protocol was approved by the Institutional
Review Board/Independent Ethics Committee at each site, and all
subjects provided written informed consent.
2.1. Inclusion/exclusion criteria
Males and females≥12 years of age were eligible if they had a
diagnosis of CF (confirmed by two positive chloride sweat tests
and/or CFTR gene analysis) and EPI (confirmed by either a
coefficient of fat absorption [CFA] b70% without supplementa-
tion or faecal elastase b50 µg/g stool within the past 12 months).
Subjects were required to be currently receiving treatment with a
commercially available pancreatic enzyme product at a stable
dose for ≥3 months and to be clinically stable without evidence
of acute respiratory disease or other acute, major medical illness.
They were required to have a stable body weight, defined as no
more than a 5% decline within the previous 3 months. Females of
child-bearing potential had to agree to continue using a medically
acceptable method of birth control.
Subjects were excluded if they had ileus or acute abdomen;
distal ileal obstruction syndrome within 6 months of enrolment;
gastrointestinal malignancy within 5 years of enrolment; ahistory of pancreatitis or fibrosing colonopathy; or known
infection with human immunodeficiency virus. Subjects aged
b18 years also were excluded if their body mass index (BMI)
percentile for their age was b10%. Prohibited treatments
included narcotic analgesics, antidiarrhoeals, antispasmodics,
laxatives, and nutritional supplements containing medium-
chain triglycerides. Stable doses of commercially available
medications influencing duodenal pH or gastric emptying were
allowed if prescribed according to the recommended dose range
and if taken for more than 4 weeks prior to the start of the study.
2.2. Study design and treatments
Following initial screening, eligible subjects continued for up
to 14 days on their usual pancreatic enzyme supplementation
before randomisation to a treatment sequence using an interactive
voice response system.
Prior to study initiation, an individualised diet to be provided
during days 1 to 5 of each crossover period was designed by a
registered dietitian at each study site. The diet was developed in
consultation with each subject and provided at least 100 g/day of
fat and included 40%of total calories from fat, as recommended in
CF Foundation nutrition guidelines [13]. Study drug intake and
dietary consumption were monitored by site personnel. Subjects
were considered noncompliant if they took less than 95% of
scheduled doses of Creon, if they consumed less than 80% of the
planned fat consumption or if the difference in fat consumption in
the two treatment periods was more than 10% based on the lower
amount consumed. Subjects were randomised 1:1 to one of two
crossover treatment sequences: Creon then placebo or placebo
then Creon. Creon 24,000 capsules were administered to achieve
a dose of 4000 lipase units/g fat based on the prescribed fat intake
per meal/snack according to the upper limit of the recommenda-
tion of CF consensus statements [13–15]. This dose was selected
to maximise fat absorption.
Subjects were either hospitalised or studied in aGeneral Clinical
Research Center unit for both crossover treatment periods. Study
medication was provided for 5 days in each crossover period, and
these periods were separated by a washout period of 3 to 14 days
during which the subjects consumed their usual diet and used their
usual pancreatic enzyme replacement product. Blinding was
maintained by provision of identical capsules and packaging for
placebo and Creon.
2.3. Efficacy assessments
The primary objective of the study was to demonstrate superior
efficacy of Creon over placebo in improving fat absorption as
measured by the CFA. To ensure accurate recording of stool
samples, subjects were given a stool marker (FD&C Blue #2,
500 mg) on the evenings of day 2 and day 5 of each crossover
period. Dietary recording was performed between administrations
of the stool markers. The stool collection was performed from the
first appearance of the dyed stool to the next appearance of the dyed
stool (Day 6 or 7 of each crossover period, depending on the
subject's intestinal motility). Stool fat was determined by the
gravimetric method.
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absorption, [16] and the treatment difference in the CFA was the
primary efficacy outcome. The CFA was calculated from the fat
intake and excretion according to the following equation:
CFAð%Þ = 100
× ½ðgrams fat intake grams fat excretionÞ=grams fat intake
Secondary efficacy outcomes included the coefficient of
nitrogen absorption (CNA), stool fat, stool weight, clinical
symptomatology, and assessments using the Clinical Global
Impression of Disease Symptoms (CGI) scale. Nitrogen intake
was determined from protein dietary intake, and nitrogen
excretion was measured in stools using standard methodology
(Kjeldahl [17]). The CNA was calculated according to the
following equation:
CNAð%Þ = 100
× ½ðgrams nitrogen intake grams nitrogen excretionÞ=grams nitrogen intake
Clinical symptomatology was determined from data
recorded daily by subjects regarding the stool frequency
(number per day), stool consistency (0=hard, 1= formed/
normal, 2=soft, 3=watery), flatulence (0=none, 1=mild,
2=moderate, 3 = severe), and abdominal pain (0=none,
1=mild, 2=moderate, 3=severe). The CGI was rated indepen-
dently by both the site investigators and the subjects at the
beginning and end of each study period according to the
following scale: 0=none (symptoms not present), 1=mild
(symptoms present but not bothersome), 2=moderate (symp-
toms bothersome), 3=severe (symptoms interfered with normal
activities), 4= incapacitating (symptoms prevented continuation
of normal activities). Subjects also answered questions
regarding stool consistency, flatulence, and abdominal pain to
determine their eligibility to enter the second crossover period.
Subjects were permitted to enter the second period only if the
scores on those parameters were no more than one level above
the baseline score.2.4. Safety evaluation
All randomised subjects who received at least one dose of
study medication were included in the safety analysis. The
safety and tolerability data collected included vital signs,
physical examination, weight, BMI, safety laboratory values
(including haematology and biochemistry), and AEs. Physical
examinations were performed during screening and at the end of
each crossover period. Laboratory safety tests were performed
during screening, at the end of the first crossover period, and at
the beginning and end of the second crossover period. AEs were
monitored beginning during the specified pre-treatment through
to the follow-up period. Laboratory samples were analysed by
Mayo Clinic Clinical Trial Services (Rochester, MN, USA).
Any AE that started or worsened during a treatment period (plus
one day) was considered treatment emergent for that treatment
arm.2.5. Statistics
Since there is no general agreement on what a clinically
meaningful change in CFA is considered, we chose the
following method to establish the correct sample size to
appropriately power the study. A 7% change in body weight is
considered clinically significant in other patient populations
[18,19]. A weight gain of 7% over 1 year in a 70-kg subject
would require an increase in the CFA of 11% to 14% based on a
diet that includes 80 to 100 g/day of fat. Thus, the minimum
clinically relevant difference in CFA between Creon and
placebo of 14% was selected for this study. Assuming a
difference of 14% and a standard deviation of 20%, the effect
size would be 0.7. A sample size of 24 had 90% power to detect
an effect size of 0.7 using a paired t-test with a 0.05 two-sided
level of significance. Thus, at least 24 subjects who completed
both crossover periods were required. To account for dropouts,
a minimum of 26 subjects (13 per treatment sequence) were
planned to be randomised.
The primary analysis was performed on the full analysis
sample, which included all randomised subjects who took at
least one dose of double-blind study medication and for whom
at least one post-baseline assessment of any efficacy parameter
was available. One patient dropped out during the first period
(on placebo) due to a medication error and was allowed a
second entry which was completed according to protocol (only
data from the second entry was used in the analysis). All
efficacy and safety variables were summarised by standard
descriptive methods.
The CFA data were analysed using analysis of variance. The
model included sequence, period, and treatment as fixed effects
and subject within sequence as a random effect. This was used
to derive an estimate of the treatment difference, 95%
confidence interval, and p value for comparison of Creon and
placebo. A test for carryover was not performed. Data were
assessed graphically (box plots, normal probability plots,
residual-by-predicted plots) to confirm normality.
Prospectively planned exploratory subanalyses also were
performed for CFA, CNA, and clinical symptomatology with
respect to subject age (ages 12–18 years vs. N18 years) and
severity of off-treatment EPI (placebo CFA ≤50% vs. N50%).
All analysis data sets and statistical output were produced
using the SAS® system Version 8.2 or higher.
3. Results
Thirty-four patients provided consent; 32 were randomised
(16 to each crossover group) and 31 subjects completed period 2
(Fig. 1). The Creon/placebo treatment sequence group had a
larger proportion of females (Table 1). Eighteen patients took
acid suppression medications during the study (9 in each
treatment sequence group).
3.1. Efficacy
CFA (least squares [LS] mean) was significantly (pb0.001)
greater with Creon compared with placebo (Table 2). All subjects
Fig. 1. Study design and patient disposition. AE: adverse event.
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≥85% with Creon irrespective of their CFA during placebo
(Fig. 2A). The mean total fat intake for days 3 to 5 of each
crossover period was similar for both treatments (mean±standard
deviation [SD]: Creon, 476.6±136.9 g; placebo, 490.6±156.6 g;
statistical significance not tested) and the mean±SD lipase dose
was 4189±732 units/g fat intake during Creon treatment. This
exceeded the target dose of 4000units/g fat due to incomplete
consumption of dietary fat provided. Expressed as a function of
body weight, subjects received a mean daily dose of 10,942.7
lipase units/kg.
No clinicallymeaningful difference inCreon treatment effect on
the CFA was observed between subjects aged 12 to 18 years and
those aged N18 years. Both groups achieved significant increases
in CFA with Creon compared with placebo (LS mean±standardTable 1
Subject characteristics at baseline.
Placebo/Creon
(n=16)
Creon/placebo
(n=16)
Total
(N=32)
Median age (range), y 21.5 (12–43) 22.5 (13–38) 22.0 (12–43)
Female, n (%) 4 (25.0) 7 (43.8) 11 (34.4)
Race, n (%)
White 16 (100) 16 (100) 32 (100)
CFA category during
placebo, n (%)
≤50 8 (50.0) 9 (60.0) 17 (54.8)
N50 8 (50.0) 6 (40.0) 14 (45.2)
Mean BMI (SD) 21.6 (3.3) 21.0 (2.0) 21.3 (2.7)
BMI: Bodymass index; SD: standard deviation; CFA: coefficient of fat absorption.error [SE] for treatment difference, 43.4±5.7% vs. 37.3±4.2%,
respectively; pb0.001 for both). Subjects with more severe EPI, as
determined by a placebo CFA of ≤50%, demonstrated a greater
effect of Creon treatment compared with subjects whose placebo
CFA was N50% (LS mean±SE for treatment difference, 52.4±
2.5% vs. 23.3±2.9%, respectively), but treatment differences were
significant in both of these subgroups (pb0.001 for both) and LS
mean CFA values during Creon treatment were similar (LSmean±
SE, 88.7±1.8% vs. 88.7±2.0%, respectively).
The CNA (LS mean) was also significantly (pb0.001)
greater with Creon treatment compared with placebo (Table 2,
Fig. 2B). The mean±SD total nitrogen intake for days 3 to 5 of
each crossover period was similar for both treatments (Creon,
58.5±21.0 g; placebo, 60.2±21.8 g; statistical significance not
tested). No clinically meaningful differences in CNA were
observed by age group (LS mean±SE for treatment difference,Table 2
Coefficient of fat and nitrogen absorption.
On Creon
(n=32 a)
On placebo
(n=31)
Treatment
difference
p value
for difference
n 31 31
LS mean CFA (SE) 88.6 (2.3) 49.6 (2.3) 39.0 (3.1) b0.001
LS mean CNA (SE) 85.1 (1.9) 49.9 (1.9) 35.2 (2.7) b0.001
CFA, coefficient of fat absorption; CNA, coefficient of nitrogen absorption; LS,
least squares.
a One subject was discontinued one day after the last dose of Creon treatment.
Fig. 2. Individual subject data for (A) coefficient of fat absorption (CFA) and (B) coefficient of nitrogen absorption (CNA) during treatment with Creon or placebo.
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N18 years subgroup; pb0.001 for both). As observed in the
analysis of CFA by severity of EPI, subjects whose placebo
CFA was ≤50% demonstrated a greater treatment effect of
Creon treatment on their CNA compared with subjects whose
placebo CFA was N50% (LS mean±SE for treatment
difference, 42.3±3.0% and 26.6±3.9%, respectively), but
treatment differences were significant in both subgroups
(pb0.001 for both) and LS mean±SE CFA values reached
similar levels with treatment (83.7±2.1% and 86.3±2.7%,
respectively; statistical significance not tested).
Stool fat, stool nitrogen, and stool weight were all significantly
lower with Creon treatment compared with placebo (LS mean±
SE stool fat, 57.9±12.2 g vs. 244.5±12.2 g; LS mean±SE stool
nitrogen, 9.0±1.1 g vs. 29.4±1.1 g; LS mean±SE stool weight,
631.1±66.5 g vs. 1587.3±66.5 g; pb0.001 for all comparisons).
Adverse clinical symptoms (stool frequency, abdominal pain,
stool consistency, and flatulence) occurred less frequently in the
Creon group compared with the placebo group. The daily stool
frequency was reduced with Creon compared with placebo (LS
mean±SE, 1.8±0.1 vs. 2.8±1.1, respectively; pb0.001). Ab-
dominal pain and flatulence were less severe and stool
consistency was less watery with Creon compared with placebo.These differences were apparent on the first day of treatment and
maintained throughout the 5-day treatment period (Fig. 3).
Compared with placebo, subjects on Creon reported significantly
more total days without abdominal pain (LSmean±SE percent of
diary days, 90.3±5.9 vs. 58.4±6.1, respectively; pb0.001),
without flatulence (LSmean±SE percent of diary days, 41.6±4.4
vs. 25.1±4.5, respectively; p=0.013), and with formed/normal
stools (LS mean±SE percent of diary days, 75.0±4.5 vs. 24.4±
4.7, respectively; pb0.001).
No clinically meaningful differences were observed by age
regarding the effects of Creon on abdominal pain, stool
consistency, and flatulence (data not shown). As observed for
the CFA and CNA, the differences between Creon and placebo
for these symptoms were greater in subjects whose placebo
CFA was ≤50% compared with subjects whose placebo CFA
was N50%; however, the sample size was too small to reach
meaningful conclusions (data not shown).
During Creon treatment, both the investigators' and the
subjects' CGI assessments reflected a stable condition with no
meaningful changes from the beginning to the end of the
treatment period (Fig. 3). In contrast, the investigators and the
subjects assessed the symptoms as worsening during treatment
with placebo (Fig. 3).
Fig. 3. Effect of Creon on abdominal pain (A, B), stool consistency (C, D), and flatulence (E, F), and Clinical Global Impression of Disease Severity (CGI) assessed by
investigators (G) and by subjects (H).
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Table 3
Treatment-emergent adverse events (TEAEs).
On Creon On placebo
n=32 (100%) n=31(100%)
Any TEAE 14 (43.8) 20 (64.5)
Serious TEAE 0 0
Discontinuation due to TEAE 1 (3.1) 0
Severe TEAE 1 (3.1) 1 (3.2)
Treatment-related TEAE 6 (18.8) 12 (38.7)
Most common TEAEa
Gastrointestinal disorder 6 (18.8) 12 (38.7)
Abnormal faeces 1 (3.1) 6 (19.4)
Flatulence 3 (9.4) 8 (25.8)
Abdominal pain 3 (9.4) 8 (25.8)
Abdominal pain, upper 0 2 (6.5)
Investigations 1 (3.1) 2 (6.5)
Weight decreased 1 (3.1) 2 (6.5)
Nervous system disorders 4 (12.5) 7 (22.6)
Headache 2 (6.3) 7 (22.6)
Dizziness 2 (6.3) 0
Respiratory/thoracic/mediastinal
disorders
4 (12.5) 1 (3.2)
Cough 2 (6.3) 0
a Occurring in ≥5% of subjects in either treatment group.
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Treatment-emergent AEs (TEAEs) and treatment-related
TEAEs had a lower overall incidence during Creon treatment
than during placebo treatment (Table 3). Two severe TEAEs
were reported for one subject: one TEAE occurred during Creon
treatment (dizziness) and one TEAE during placebo treatment
(severe upper abdominal pain).
During the washout period, one subject in the Creon/placebo
treatment sequence was discontinued per protocol one day after
the last dose of Creon due to a TEAE (weight decrease) that was
considered unlikely related to study drug (Table 3). One subject
in the Creon/placebo treatment sequence experienced serious
AEs (duodenitis and gastritis) more than 2 weeks after the last
dose of Creon. These AEs were considered unrelated to study
participation. Analysis of AEs did not reveal any TEAEs with a
clinically meaningfully greater incidence in the Creon group
compared with the placebo group, and no cases of hypersen-
sitivity were reported. No meaningful treatment group differ-
ences were observed for any of the laboratory parameters or
vital signs. No deaths occurred in this study.
4. Discussion
These data demonstrate that Creon 24,000 capsules are an
effective treatment for maldigestion with resultant malabsorp-
tion associated with EPI due to CF. Compared with placebo, fat
absorption was significantly improved, as was nitrogen
absorption (a marker for protein absorption) and overall
symptoms of maldigestion. Creon was safe and well tolerated
within the limited duration of the study; fewer TEAEs were
observed with Creon treatment compared with placebo.
The CFA values achieved on Creon treatment, as well as
differences in CFA values observed between Creon and placebo,were consistent with those observed in a double-blind study of
Creon 20 published by Stern et al. [7]. Similar CFA values were
achieved with Creon 10 in two crossover studies that included
subjects b7 years of age (78.0%and 90.5%) and subjects≥7 years
of age (CFA 83.1% and 91.8%) [6]. The average CFA achieved
with Creon by subjects with CF in this study was also within the
range previously observed in healthy adult subjects (86.6%–
98.2%), albeit slightly lower than the mean CFA observed in those
subjects (93.5%) [20].
The use of CNA to measure protein absorption is not as well
characterised, although increases in CNA have been observed
with pancreatic enzyme supplements in previous studies
[21,22]. The significant treatment-associated differences in
the CNA in the current study suggest that Creon was effective
in improving protein digestion and absorption. As observed for
CFA, the average CNA achieved with Creon by subjects in this
study was within the range previously observed in healthy adult
subjects (78.0%–94.7%) and slightly lower than the mean
CNA observed in those subjects (88.1%) [20]. Ultimately, this
improved nitrogen/protein absorption suggests nutritional
benefits of treatment in persons with CF.
The upper limit of the lipase dose range recommended by CF
Foundation consensus reports for this age group was selected
for this study in order to maximise fat absorption. The mean
dose in the current study slightly exceeded the upper limit of
4000 lipase units/g fat/day [13] as a result of incomplete
consumption of the meals provided. The upper limit of dosing
recommendations for pancreatic enzyme replacement are based
on preventing the occurrence of fibrosing colonopathy, which
may be associated with extremely high doses of high-strength
pancreatic enzyme products [8]. Given the evidence that
enzyme preparations were previously overfilled [23], dosing
guidelines for pancreatic enzyme replacement therapy in
patients with CF may require revisiting.
Although this studywas of limited duration, no issues relating to
either safety or tolerability were noted and no unexpected TEAEs
were observed. In fact, the apparent treatment-associated improve-
ment in symptomatology and in the CGI were consistent with the
fewer TEAEs observed with Creon compared with placebo.
One limitation of this study is the relatively high dose chosen,
coupled with dosing per gram of fat rather than per kilogram of
body weight, may not be easily compared with dosing practices
commonly used in the clinical setting. There are a lack of dose-
response data for pancreatic enzyme replacement therapies
because of the complexity of designing a study that balances
the variability introduced by patient-level factors, dietary factors,
and dose. In addition, CFA is not routinely determined in the
course of clinical practice so the results from any short-term study
with a CFA primary endpoint is of limited value in the
management of individual patients. Finally, the short duration
of the study does not allow conclusions to be drawn regarding
long-term tolerability or symptomatology.
Taken together, the data in this study provide strong evidence for
the effectiveness of Creon 24,000 capsules at a dose of
approximately 4000 lipase units/g fat in the treatment of EPI in
subjects with CF. In addition, these data tend to support the
consistency of efficacy of these capsules with Creon 20.
377B.C. Trapnell et al. / Journal of Cystic Fibrosis 8 (2009) 370–377Role of the funding source
This study was funded by Solvay Pharmaceuticals, Inc. who
designed the study and directed the data analysis. In addition,
together with study investigators, Solvay Pharmaceuticals
participated in the collection and interpretation of data, in the
writing of the manuscript, and in the decision to submit the
manuscript for publication.
Conflict of interest statement
Bruce Trapnell and Gavin Graff have no conflicts to report.
Karen Maguiness is a consultant to both Solvay Pharmaceu-
ticals and Altus Pharmaceuticals. David Boyd and Steven Caras
are employees of Solvay Pharmaceuticals, Inc., Marietta, GA,
USA. Katrin Beckmann is an employee of Solvay Pharmaceu-
ticals GmbH, Hannover, Germany.
Acknowledgements
Other study site investigators: Richard Ahrens, University of
Iowa Hospitals and Clinics, Iowa City, IA, USA; Bruce Barnett,
Toledo Children's Hospital, Toledo, OH, USA; Daniel Layish,
Florida Hospital, Orlando, FL, USA; John McNamara,
Children's Respiratory and Critical Care Specialists, Minnea-
polis, MN, USA; Santiago Reyes, Respiratory Diseases of
Children and Adolescents, Oklahoma City, OK, USA; Barry
Steinmetz, Long Beach Medical Center, Long Beach, CA,
USA; William Yee, Tufts New England Medical Center,
Boston, MA, USA; Robert Zanni, The Children's Hospital at
Monmouth Medical Center, Long Branch, NJ, USA.
The authors thank Lorrie Duan for consultation and
assistance in training study site personnel. Editorial support
was provided by Ed Parr, PhD, Envision Scientific Solutions,
Southport, CT and funded by Solvay Pharmaceuticals.
References
[1] Walkowiak J, Sands D, Nowakowska A, Piotrowski R, Zybert K, Herzig
KH, et al. Early decline of pancreatic function in cystic fibrosis patients
with class 1 or 2 CFTR mutations. J Pediatr Gastroenterol Nutr
2005;40:199–201.
[2] Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacother-
apy. Pharmacotherapy 2007;27:910–20.
[3] Baker SS, Borowitz D, Baker RD. Pancreatic exocrine function in patients
with cystic fibrosis. Curr Gastroenterol Rep 2005;7:227–33.
[4] Wilschanski M. Nutrition in cystic fibrosis. In: Koletzko B, editor.
Pediatric Nutrition in Practice. Basel, Switzerland: Karger; 2008. p. 224–8.
[5] Safdi M, Bekal PK, Martin S, Saeed ZA, Burton F, Toskes PP. The effects
of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a
multicenter, placebo-controlled, parallel group trial in subjects with
chronic pancreatitis. Pancreas 2006;33:156–62.
[6] Sander-Struckmeier S, Boyd D, Caras S. Pancrelipase delayed-release
capsules (CREON®): efficacy and safety in children less than 7 years old
with pancreatic exocrine insufficiency due to cystic fibrosis. Presented at:
21st Annual Meeting of the North American Society for PediatricGastroenterology, Hepatology and Nutrition; November 13–15, 2008. San
Diego, CA.
[7] Stern RC, Eisenberg JD, Wagener JS, Ahrens R, Rock M, doPico G, et al.
A comparison of the efficacy and tolerance of pancrelipase and placebo in
the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine
pancreatic insufficiency. Am J Gastroenterol 2000;95:1932–8.
[8] FitzSimmons SC, Burkhart GA, Borowitz D, Grand RJ, Hammerstrom T,
Durie PR, et al. High-dose pancreatic enzyme supplements and fibrosing
colonopathy in children with cystic fibrosis. New Engl J Med
1997;336:1283–9.
[9] U.S. Food and Drug Administration. Questions and answers on exocrine
pancreatic insufficiency drug products. http://www.fda.gov/CDER/
DRUG/infopage/pancreatic_drugs/pancreatic_QA.htm. Published April
27, 2004. Accessed March 9, 2009.
[10] U.S. Food and Drug Administration. FDA requires pancreatic extract
manufacturers to submit marketing applications. FDA News. http://www.
fda.gov/bbs/topics/news/2004/NEW01058.html. Published April 27,
2004. Accessed 8 August 2008.
[11] U.S. Food and Drug Administration Center for Drug Evaluation and
Research. Guidance for Industry: Exocrine Pancreatic Insufficiency Drug
Products— Submitting NDAs. http://www.fda.gov/cder/guidance/6275fnl.
htm. Published April 13, 2006. Accessed March 9 2009.
[12] Trapnell BC, Maguiness K, Graff GR. Efficacy and safety of a new
formulation of CREON® in patients with exocrine pancreatic insufficiency
due to CF. J Cystic Fibrosis 2009;8:S80.
[13] Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for
pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr
2002;35:246–59.
[14] Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman
HG, et al. Nutrition in patients with cystic fibrosis: a European Consensus.
J Cyst Fibros 2002;1:51–75.
[15] Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Clinical
Practice Guidelines on Growth and Nutrition Subcommittee; Ad Hoc
Working Group. Evidence-based practice recommendations for nutrition-
related management of children and adults with cystic fibrosis and
pancreatic insufficiency: results of a systematic review. J Am Diet Assoc
2008;108:832–9.
[16] Borowitz D, Durie PR, Clarke LL, Werlin SL, Taylor CJ, Semler J, et al.
Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr
Gastroenterol Nutr 2005;41:273–85.
[17] Kjeldahl JT. A new method for the determination of nitrogen in organic
matter. Z Anal Chem 1883;22:366–82.
[18] Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the
literature. J Clin Psychiatry 2001;62(Suppl 7):22–31.
[19] Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM,
Walker EA, et al. The Diabetes Prevention Program Research Group.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or
metformin. N Engl J Med 2002;346:393–403.
[20] Borowitz D, Konstan MW, O'Rourke MS, Cohen M, Hendeles L, Murray
FT. Coefficients of fat and nitrogen absorption in healthy subjects and
individuals with cystic fibrosis. J Pediatr Pharmacol Ther 2007;12:47–52.
[21] Heubi JE, Boas SR, Blake K, Nasr SZ, Woo MS, Graff GR, et al. 246
EUR-1008 (a new pancreatic enzyme product, PEP) was shown to be safe
and effective in cystic fibrosis (CF) patients with exocrine pancreatic
insufficiency (EPI). J Cystic Fibrosis 2007;6:S61.
[22] Borowitz D, Goss CH, Limauro S, Konstan MW, Blake K, Casey S, et al.
Study of a novel pancreatic enzyme replacement therapy in pancreatic
insufficient subjects with cystic fibrosis. J Pediatr 2006;149:658–62.
[23] Kuhn RJ, Eyting S, Henniges F, Potthoff A. In vitro comparison of
physical parameters, enzyme activity, acid resistance, and pH dissolution
characteristics of enteric-coated pancreatic enzyme preparations: implica-
tions for clinical variability and pharmacy substitution. J Pediatr
Pharmacol Ther 2007;12:115–28.
